CN111542519A - 一种吲哚衍生物的晶型及其制备方法和用途 - Google Patents

一种吲哚衍生物的晶型及其制备方法和用途 Download PDF

Info

Publication number
CN111542519A
CN111542519A CN201980007825.7A CN201980007825A CN111542519A CN 111542519 A CN111542519 A CN 111542519A CN 201980007825 A CN201980007825 A CN 201980007825A CN 111542519 A CN111542519 A CN 111542519A
Authority
CN
China
Prior art keywords
compound
degrees
crystalline
mediated disease
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980007825.7A
Other languages
English (en)
Other versions
CN111542519B (zh
Inventor
姚元山
陈斌
高峰
陈远
徐然
杨成帅
张生
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN111542519A publication Critical patent/CN111542519A/zh
Application granted granted Critical
Publication of CN111542519B publication Critical patent/CN111542519B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一种吲哚衍生物（化合物1）的晶型及其药物组合物和制备方法被公开，所述晶型用于制备治疗与CRTH2受体相关病症的药物。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201980007825.7A 2018-01-19 2019-01-18 一种吲哚衍生物的晶型及其制备方法和用途 Active CN111542519B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018100527751 2018-01-19
CN201810052775 2018-01-19
PCT/CN2019/072357 WO2019141241A1 (zh) 2018-01-19 2019-01-18 一种吲哚衍生物的晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN111542519A true CN111542519A (zh) 2020-08-14
CN111542519B CN111542519B (zh) 2021-11-02

Family

ID=67301280

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980007825.7A Active CN111542519B (zh) 2018-01-19 2019-01-18 一种吲哚衍生物的晶型及其制备方法和用途

Country Status (8)

Country Link
US (1) US11034681B2 (zh)
EP (1) EP3741754A4 (zh)
JP (1) JP7296970B2 (zh)
KR (1) KR20200111733A (zh)
CN (1) CN111542519B (zh)
AU (1) AU2019209725B2 (zh)
CA (1) CA3088917A1 (zh)
WO (1) WO2019141241A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101087784A (zh) * 2004-09-21 2007-12-12 阿特西斯公司 显示crth2受体拮抗性的吲哚乙酸及其应用
WO2018014869A1 (zh) * 2016-07-21 2018-01-25 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
CN107936004A (zh) * 2017-11-30 2018-04-20 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101087784A (zh) * 2004-09-21 2007-12-12 阿特西斯公司 显示crth2受体拮抗性的吲哚乙酸及其应用
WO2018014869A1 (zh) * 2016-07-21 2018-01-25 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
CN107936004A (zh) * 2017-11-30 2018-04-20 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类衍生物

Also Published As

Publication number Publication date
US20200347040A1 (en) 2020-11-05
EP3741754A1 (en) 2020-11-25
JP2021510718A (ja) 2021-04-30
WO2019141241A1 (zh) 2019-07-25
US11034681B2 (en) 2021-06-15
KR20200111733A (ko) 2020-09-29
JP7296970B2 (ja) 2023-06-23
CA3088917A1 (en) 2019-07-25
AU2019209725A1 (en) 2020-08-06
EP3741754A4 (en) 2021-06-09
AU2019209725B2 (en) 2023-03-09
CN111542519B (zh) 2021-11-02

Similar Documents

Publication Publication Date Title
EP3476841A1 (en) Crystals of aniline pyrimidine compound serving as egfr inhibitor
CN111542519B (zh) 一种吲哚衍生物的晶型及其制备方法和用途
CN113439083B (zh) 二芳基硫代乙内酰脲化合物结晶
CN117797146A (zh) Sarm1酶活性抑制剂及其在神经退行性疾病中的应用
US11261196B2 (en) Salt serving as AKT inhibitor and crystal thereof
Poddar et al. Synthesis and biological evaluation of 2-methyl-1Hbenzimidazole and 1H-benzimidazol-2-yl-methanol
WO2018090974A1 (zh) 一种具有抗癌作用的化合物及其制备方法和应用
CN111065630B (zh) 一种内磺酰胺化合物结晶
WO2022237808A1 (zh) 吡咯并嘧啶类化合物的晶型及其制备方法
WO2022247885A1 (zh) 三并杂环类化合物的结晶和盐及其应用
RU2810214C2 (ru) Кристалл диарилтиогидантоинового соединения
CN111484505B (zh) 一种双环RORγ抑制剂的盐酸盐结晶型
CN111217748B (zh) 一种螺环二氢异喹啉甲酰胺类衍生物的晶型及其制备方法
TW202100513A (zh) 氘原子取代的吲哚甲酰胺類衍生物的晶型及其製備方法
WO2023093861A1 (zh) Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
WO2024078294A1 (zh) 酮酰胺衍生物的无定型及其制备方法
WO2023207944A1 (zh) Fgfr4抑制剂的晶型及应用
RU2818103C2 (ru) Соль ингибитора syk и ее кристаллическая форма
WO2023046072A1 (zh) 咪唑啉酮衍生物的晶型
CN111757871B (zh) 一种Caspase抑制剂的结晶
EP4361140A1 (en) Pharmaceutically acceptable salt and crystal form of fused pyridine ring derivative and preparation method therefor
WO2021023271A1 (zh) 作为前列环素受体激动剂的化合物的晶型及其制备方法
TW202404610A (zh) 一種硼酸酯衍生物的結晶、其製備方法及用途
CN113045490A (zh) 结晶型硝羟喹啉及其制备方法和用途
WO2022268180A1 (zh) 嘧啶并含氮六元芳香杂环类化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant